PX1 Research supplies analytical-grade CJC-1295 and Ipamorelin pre-blended research peptides synthesized for rigorous in vitro and preclinical laboratory assays. Investigating dual-pathway somatotrophic signaling requires ultra-pure, lot-verified compounds free of synthesis sequence truncations or bacterial endotoxins.
PX1 Research supplies analytical-grade CJC-1295 and Ipamorelin pre-blended research peptides synthesized for rigorous in vitro and preclinical laboratory assays. Investigating dual-pathway somatotrophic signaling requires ultra-pure, lot-verified compounds free of synthesis sequence truncations or bacterial endotoxins.
A CJC-1295 Ipamorelin blend for sale refers to a lyophilized combination of two synthetic research peptides—a growth hormone-releasing hormone (GHRH) analog and a selective ghrelin receptor agonist—designed for in vitro and animal research evaluating dual-pathway somatotrophic stimulation, pulsed GH secretion, and downstream IGF-1 expression.
When sourcing a CJC-1295 Ipamorelin blend for institutional or laboratory study, purity and accurate molar ratio verification are paramount. Inconsistent ratio blending or improper lyophilization techniques can introduce baseline variance in receptor binding assays, compromising experimental reproducibility across cell cultures or animal models. PX1 Research delivers laboratory-grade research compounds manufactured in US-based, GMP-compliant facilities under strict quality controls.
Every batch undergoes independent third-party testing via High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) to verify exact sequence identity and purity exceeding 99%. Laboratories can review batch-specific documentation, including endotoxin quantification and purity profiles, directly through our centralized research peptide library.
In endocrine research, somatotroph cells in the anterior pituitary gland express distinct cell-surface receptors that independently govern the synthesis and pulsatile release of endogenous growth hormone (GH). The primary signaling pathways involve the growth hormone-releasing hormone receptor (GHRH-R) and the growth hormone secretagogue receptor (GHS-R1a). Combining CJC-1295 No DAC with Ipamorelin allows investigators to engage both receptor classes concurrently.
Preclinical models demonstrate that simultaneous activation of GHRH-R and GHS-R1a produces a synergistic release of GH rather than a simple additive response. The binding of CJC-1295 to GHRH-R stimulates intracellular adenylate cyclase, elevating cyclic adenosine monophosphate (cAMP) and activating protein kinase A (PKA). Concurrently, Ipamorelin binds GHS-R1a, triggering phosphoinositide hydrolysis, increasing intracellular free calcium ions (Ca2+), and activating protein kinase C (PKC).
This dual-cascade engagement amplifies gene transcription for hormone synthesis while facilitating exocytosis of GH-containing secretory vesicles. For researchers evaluating receptor cross-talk or downstream tissue repair signaling, utilizing a pre-mixed blend ensures identical stoichiometric delivery to experimental target tissues.
CJC-1295 is a modified 29-amino-acid tetrasubstituted peptide derivative of natural GHRH (1-29). Studied as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research, its structure incorporates specific amino acid substitutions at positions 2, 8, 15, and 27. These substitutions protect the molecule against rapid enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV), markedly extending its biological half-life compared to native GHRH.
In rodent and cell culture models, CJC-1295 maintains sustained affinity for the GHRH receptor. By providing continuous GHRH receptor stimulation, it promotes stable gene expression of insulin-like growth factor 1 (IGF-1) in hepatic and extrahepatic tissues. Detailed physiological mechanisms regarding terminal half-life differences between modified forms are detailed in our CJC-1295 mechanism guide.
Investigators utilize CJC-1295 to evaluate long-term cellular proliferation, collagen matrix synthesis, and nitrogen retention assays. Unlike native GHRH, which degrades within minutes in serum, the enhanced stability of CJC-1295 allows stable signaling kinetics across extended in vitro observation windows.
Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) engineered specifically for selective agonism at the growth hormone secretagogue receptor (GHS-R1a). Preclinical literature highlights Ipamorelin for its distinct receptor selectivity profile; unlike earlier secretagogues, it does not induce significant elevations in plasma cortisol, adrenocorticotropic hormone (ACTH), or prolactin during pituitary signaling assays.
In vitro studies demonstrate that Ipamorelin mimics the physiological action of ghrelin by stimulating episodic, pulsatile GH secretion from pituitary somatotrophs. Its high specificity minimizes off-target signaling events in secondary endocrine pathways, making it an ideal control compound for isolated growth hormone axis experiments. Further exploration of receptor activation dynamics is available in our overview of GHRP receptor signaling.
By binding GHS-R1a without disrupting glucocorticoid homeostasis, Ipamorelin provides researchers with a clean experimental tool to measure isolated somatotrophic outputs, lipid oxidation rates, and cellular metabolic flux without confounding systemic stress markers.
In vitro data indicate that co-administration of GHRH analogs and GHS-R agonists yields a non-linear increase in total GH output. Animal studies evaluating pituitary perfusion models show that when GHRH-R and GHS-R1a are stimulated simultaneously, the total peak concentration of growth hormone released significantly exceeds the mathematical sum of either peptide administered alone.
This synergistic phenomenon is attributed to intracellular signal convergence. Elevated cAMP levels from CJC-1295 signaling sensitize the secretory apparatus to the Ca2+ influx initiated by Ipamorelin. Preclinical models evaluating tissue regeneration demonstrate enhanced markers of protein translation, satellite cell activation, and extracellular matrix remodeling when dual-pathway secretagogues are deployed.
Additionally, rodent models suggest that sustained GHRH agonism combined with intermittent GHRP pulses helps preserve normal feedback loop responsiveness, preventing receptor desensitization or downregulation during multi-week experimental protocols.
Evaluating secretagogue combinations requires comparing their signaling kinetics, half-life, and receptor selectivity against single-agent options. While a CJC-1295 and Ipamorelin blend offers balanced, highly selective dual-pathway activation, researchers frequently compare this combination with other GHRH analogs and secretagogues such as sermorelin, ghrp-2, and tesamorelin.
Sermorelin represents the baseline 29-amino-acid sequence of GHRH; however, it exhibits a significantly shorter plasma half-life due to rapid DPP-IV clearance. Tesamorelin features a trans-3-hexenoic acid modification that optimizes hepatic lipid metabolism assays but lacks the concurrent GHS-R1a engagement provided by an added secretagogue. On the secretagogue side, GHRP-2 demonstrates potent GH release but exhibits moderate cross-reactivity with cortisol and prolactin pathways, whereas Ipamorelin maintains complete receptor selectivity.
For laboratories seeking comprehensive somatotropic stimulation without off-target adrenal pathway activation, the CJC-1295 and Ipamorelin pairing provides the most selective, reproducible dual-agent profile available for preclinical research.
PX1 Research enforces stringent purity protocols for all research peptides. Raw materials are synthesized using advanced solid-phase peptide synthesis (SPPS) methodologies, followed by multi-stage purification via preparative reverse-phase HPLC (RP-HPLC). This process removes incomplete amino acid sequences, trifluoroacetate (TFA) salts, and organic impurities.
Each batch of our CJC-1295 Ipamorelin blend is subjected to high-resolution Mass Spectrometry to confirm exact molecular weight match for both peptide components (CJC-1295 without DAC MW: 3357.93 g/mol; Ipamorelin MW: 711.86 g/mol). HPLC analytical runs confirm overall chemical purity equal to or exceeding 99.0%.
Furthermore, our compounds undergo Chromogenic Recombinant Limulus Amebocyte Lysate (rLAL) testing to ensure bacterial endotoxin levels remain strictly below < 0.01 EU/mg. All analytical procedures are performed in independent, ISO 17025-accredited analytical laboratories in the United States, with verifiable Certificates of Analysis (COAs) attached to every lot.
Lyophilized peptide blends are sensitive to moisture, temperature fluctuations, and physical shear forces. Upon delivery, unopened vials should be stored in a dry, dark environment at -20°C for long-term stability. Prior to reconstitution, vials must be allowed to equilibrate to room temperature to prevent condensation from introducing moisture into the cake.
Reconstitution should be performed under a certified laminar flow hood using sterile, laboratory-grade Bacteriostatic Water (0.9% benzyl alcohol) or sterile normal saline, depending on the requirements of the specific cell culture or animal assay. The diluent should be directed gently along the glass wall of the vial rather than sprayed directly onto the lyophilized powder. The vial should be gently swirled until fully dissolved; mechanical vortexing must be avoided as it can induce protein aggregation or peptide shear.
Once reconstituted, aqueous peptide solutions should be aliquoted into single-use polypropylene microtubes to prevent repeated freeze-thaw cycles. Reconstituted aliquots must be stored at 2°C to 8°C and utilized within 30 days, or frozen at -80°C for extended experimental timelines.
Securing high-purity research compounds requires strict verification of vendor analytical protocols. Academic institutions, pharmaceutical research facilities, and contract research organizations (CROs) should avoid suppliers that fail to provide lot-specific COAs, mass spectra, and verified endotoxin measurements.
PX1 Research provides seamless procurement for research laboratories. All orders ship directly from our state-of-the-art dispatch facilities in California and Arizona. Orders placed Monday through Friday before 3:00 PM EST ship same-day to ensure minimal transit time and temperature control integrity.
For high-volume laboratory requirements, core facilities, or ongoing animal trial supply, research managers can establish institutional pricing via our wholesale lab accounts portal. Our scientific support team provides full batch traceability and complete analytical documentation for every order.
What is the primary ratio of CJC-1295 to Ipamorelin in this blend?
PX1 Research supplies a standardized 1:1 molar ratio formulation (typically 5mg CJC-1295 No DAC paired with 5mg Ipamorelin, total 10mg lyophilized cake) optimized for dual GHRH-R and GHS-R1a receptor saturation in preclinical research models.
How is the purity of the CJC-1295 Ipamorelin blend verified?
Every lot undergoes independent third-party analysis using RP-HPLC to measure chemical purity (>99%) and Electrospray Ionization Mass Spectrometry (ESI-MS) to verify precise molecular mass for both peptide sequences.
Does CJC-1295 in this blend contain DAC (Drug Affinity Complex)?
Our standard blend utilizes CJC-1295 Without DAC (also known as Modified GRF 1-29). This allows researchers to study rapid, physiological GH pulses rather than prolonged, continuous elevation.
What are the bacterial endotoxin limits for PX1 Research peptides?
All PX1 Research compounds are verified via rLAL endotoxin assays to ensure levels remain below < 0.01 EU/mg, preventing endotoxin-induced inflammatory responses in sensitive in vitro cell lines or animal assays.
How should the lyophilized peptide blend be stored upon arrival?
Unreconstituted, lyophilized vials should be stored at -20°C in a desiccated environment. Under these conditions, the peptide cake remains stable for up to 24 months.
What diluent should be used for laboratory reconstitution?
Reconstitution is typically performed using sterile Bacteriostatic Water (0.9% benzyl alcohol) for multi-dose benchtop assays or sterile 0.9% Sodium Chloride for sensitive cell culture media applications.
Where are PX1 Research peptides manufactured and shipped from?
All PX1 Research peptides are synthesized in ISO 17025-accredited, GMP-compliant facilities within the United States. Orders ship directly from our inventory centers in California and Arizona with same-day shipping for orders placed M–F before cutoff.
Can these compounds be used for human clinical applications?
No. All products sold by PX1 Research are strictly designated for in vitro, animal, and laboratory research use only. They are not intended for human consumption, clinical trials, or therapeutic procedures.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.